Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

Bruton tyrosine kinase (BTK) is expressed in B cells and innate immune cells, acting as an essential signaling element in multiple immune cell pathways. Selective BTK inhibition has the potential to target multiple immune-mediated disease pathways. Rilzabrutinib is an oral, reversible, covalent BTK...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunol
Main Authors: Langrish, Claire L., Bradshaw, J. Michael, Francesco, Michelle R., Owens, Timothy D., Xing, Yan, Shu, Jin, LaStant, Jacob, Bisconte, Angelina, Outerbridge, Catherine, White, Stephen D., Hill, Ronald J., Brameld, Ken A., Goldstein, David M., Nunn, Philip A.
Formato: Artigo
Idioma:Inglês
Publicado em: AAI 2021
Assuntos:
Autoimmunity
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7980532/
https://ncbi.nlm.nih.gov/pubmed/33674445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.2001130
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados